Prevalence and prognosis of hypoxia‐inducible factor‐2α (HIF‐2α) pathway gene mutations across advanced solid tumors

Introduction Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF‐2α are poorly understood, with limited understanding of the prevalence and clini...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer medicine (Malden, MA) Jg. 13; H. 11; S. e7358 - n/a
Hauptverfasser:	Zhong, Wenjun, Ma, Jiemin, Chen, Cai, Dettman, E. J., Cristescu, Razvan, Naik, Girish S., Jin, Fan, Shao, Changxia
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States John Wiley & Sons, Inc 01.06.2024 John Wiley and Sons Inc Wiley
Schlagworte:	Adult Aged Basic Helix-Loop-Helix Transcription Factors - genetics Bladder cancer Cancer therapies Colorectal cancer Datasets Electronic health records Endometrial cancer epidemiology Female Gastric cancer Genes HIF‐2α Humans Hypoxia Hypoxia-inducible factors Kidney cancer Liver cancer Lung cancer Male Medical prognosis Melanoma Mesothelioma Metastases Metastasis Middle Aged Mutation Neoplasms - epidemiology Neoplasms - genetics Neoplasms - mortality Neoplasms - pathology oncology Ovaries Patients Point mutation Population Population studies Prevalence Prognosis Prostate Renal cell carcinoma Retrospective Studies Solid tumors Tumors United States > US epidemiology prevalence HIF‐2α prognosis oncology
ISSN:	2045-7634, 2045-7634
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Introduction Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF‐2α are poorly understood, with limited understanding of the prevalence and clinical prognosis. Methods This retrospective observational study used a de‐identified nationwide (US‐based) clinico‐genomic database (CGDB) across 15 available tumor types. Results Among the 9467 adult patients with advanced/metastatic solid tumors included in the analysis, any mutation at the above‐mentioned six genes was observed in 1.8% (95% CI: 1.5–2.1) of patients. The mutation prevalence ranged from 0.05% of SDHD to 0.93% of VHL. When further stratified by tumor type, the prevalence of gene mutation in each tumor type was well below 1%, except for VHL with 44% in renal cell carcinomas (RCC). Excluding RCC, the prevalence of any HIF‐2α gene mutations in the study population was 0.9% (95% CI: 0.8–1.2). The median overall survival (OS) from 1 and 2 L therapy among patients with any HIF‐2α gene mutation was 14.5 (95% CI: 11.5–24.2) and 9.3 (95% CI: 6.0–18.1) months, respectively, compared with 13.4 (95% CI: 12.9–13.9) and 9.8 (95% CI: 9.3–10.4) months among patients without HIF‐2α gene mutations. Discussion and Conclusions The prevalence of HIF‐2α related gene mutations was generally low (<1%) across the 15 solid tumor types, except for VHL in RCC. No significant association between HIF‐2α gene mutation status and OS was identified among patients evaluated in this study.
AbstractList	Hypoxia-inducible factor-2α (HIF-2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF-2α are poorly understood, with limited understanding of the prevalence and clinical prognosis. This retrospective observational study used a de-identified nationwide (US-based) clinico-genomic database (CGDB) across 15 available tumor types. Among the 9467 adult patients with advanced/metastatic solid tumors included in the analysis, any mutation at the above-mentioned six genes was observed in 1.8% (95% CI: 1.5-2.1) of patients. The mutation prevalence ranged from 0.05% of SDHD to 0.93% of VHL. When further stratified by tumor type, the prevalence of gene mutation in each tumor type was well below 1%, except for VHL with 44% in renal cell carcinomas (RCC). Excluding RCC, the prevalence of any HIF-2α gene mutations in the study population was 0.9% (95% CI: 0.8-1.2). The median overall survival (OS) from 1 and 2 L therapy among patients with any HIF-2α gene mutation was 14.5 (95% CI: 11.5-24.2) and 9.3 (95% CI: 6.0-18.1) months, respectively, compared with 13.4 (95% CI: 12.9-13.9) and 9.8 (95% CI: 9.3-10.4) months among patients without HIF-2α gene mutations. The prevalence of HIF-2α related gene mutations was generally low (<1%) across the 15 solid tumor types, except for VHL in RCC. No significant association between HIF-2α gene mutation status and OS was identified among patients evaluated in this study. IntroductionHypoxia-inducible factor-2α (HIF-2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF-2α are poorly understood, with limited understanding of the prevalence and clinical prognosis.MethodsThis retrospective observational study used a de-identified nationwide (US-based) clinico-genomic database (CGDB) across 15 available tumor types.ResultsAmong the 9467 adult patients with advanced/metastatic solid tumors included in the analysis, any mutation at the above-mentioned six genes was observed in 1.8% (95% CI: 1.5–2.1) of patients. The mutation prevalence ranged from 0.05% of SDHD to 0.93% of VHL. When further stratified by tumor type, the prevalence of gene mutation in each tumor type was well below 1%, except for VHL with 44% in renal cell carcinomas (RCC). Excluding RCC, the prevalence of any HIF-2α gene mutations in the study population was 0.9% (95% CI: 0.8–1.2). The median overall survival (OS) from 1 and 2 L therapy among patients with any HIF-2α gene mutation was 14.5 (95% CI: 11.5–24.2) and 9.3 (95% CI: 6.0–18.1) months, respectively, compared with 13.4 (95% CI: 12.9–13.9) and 9.8 (95% CI: 9.3–10.4) months among patients without HIF-2α gene mutations.Discussion and ConclusionsThe prevalence of HIF-2α related gene mutations was generally low (<1%) across the 15 solid tumor types, except for VHL in RCC. No significant association between HIF-2α gene mutation status and OS was identified among patients evaluated in this study. Introduction Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF‐2α are poorly understood, with limited understanding of the prevalence and clinical prognosis. Methods This retrospective observational study used a de‐identified nationwide (US‐based) clinico‐genomic database (CGDB) across 15 available tumor types. Results Among the 9467 adult patients with advanced/metastatic solid tumors included in the analysis, any mutation at the above‐mentioned six genes was observed in 1.8% (95% CI: 1.5–2.1) of patients. The mutation prevalence ranged from 0.05% of SDHD to 0.93% of VHL. When further stratified by tumor type, the prevalence of gene mutation in each tumor type was well below 1%, except for VHL with 44% in renal cell carcinomas (RCC). Excluding RCC, the prevalence of any HIF‐2α gene mutations in the study population was 0.9% (95% CI: 0.8–1.2). The median overall survival (OS) from 1 and 2 L therapy among patients with any HIF‐2α gene mutation was 14.5 (95% CI: 11.5–24.2) and 9.3 (95% CI: 6.0–18.1) months, respectively, compared with 13.4 (95% CI: 12.9–13.9) and 9.8 (95% CI: 9.3–10.4) months among patients without HIF‐2α gene mutations. Discussion and Conclusions The prevalence of HIF‐2α related gene mutations was generally low (<1%) across the 15 solid tumor types, except for VHL in RCC. No significant association between HIF‐2α gene mutation status and OS was identified among patients evaluated in this study. Abstract Introduction Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF‐2α are poorly understood, with limited understanding of the prevalence and clinical prognosis. Methods This retrospective observational study used a de‐identified nationwide (US‐based) clinico‐genomic database (CGDB) across 15 available tumor types. Results Among the 9467 adult patients with advanced/metastatic solid tumors included in the analysis, any mutation at the above‐mentioned six genes was observed in 1.8% (95% CI: 1.5–2.1) of patients. The mutation prevalence ranged from 0.05% of SDHD to 0.93% of VHL. When further stratified by tumor type, the prevalence of gene mutation in each tumor type was well below 1%, except for VHL with 44% in renal cell carcinomas (RCC). Excluding RCC, the prevalence of any HIF‐2α gene mutations in the study population was 0.9% (95% CI: 0.8–1.2). The median overall survival (OS) from 1 and 2 L therapy among patients with any HIF‐2α gene mutation was 14.5 (95% CI: 11.5–24.2) and 9.3 (95% CI: 6.0–18.1) months, respectively, compared with 13.4 (95% CI: 12.9–13.9) and 9.8 (95% CI: 9.3–10.4) months among patients without HIF‐2α gene mutations. Discussion and Conclusions The prevalence of HIF‐2α related gene mutations was generally low (<1%) across the 15 solid tumor types, except for VHL in RCC. No significant association between HIF‐2α gene mutation status and OS was identified among patients evaluated in this study. Hypoxia-inducible factor-2α (HIF-2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF-2α are poorly understood, with limited understanding of the prevalence and clinical prognosis.INTRODUCTIONHypoxia-inducible factor-2α (HIF-2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF-2α are poorly understood, with limited understanding of the prevalence and clinical prognosis.This retrospective observational study used a de-identified nationwide (US-based) clinico-genomic database (CGDB) across 15 available tumor types.METHODSThis retrospective observational study used a de-identified nationwide (US-based) clinico-genomic database (CGDB) across 15 available tumor types.Among the 9467 adult patients with advanced/metastatic solid tumors included in the analysis, any mutation at the above-mentioned six genes was observed in 1.8% (95% CI: 1.5-2.1) of patients. The mutation prevalence ranged from 0.05% of SDHD to 0.93% of VHL. When further stratified by tumor type, the prevalence of gene mutation in each tumor type was well below 1%, except for VHL with 44% in renal cell carcinomas (RCC). Excluding RCC, the prevalence of any HIF-2α gene mutations in the study population was 0.9% (95% CI: 0.8-1.2). The median overall survival (OS) from 1 and 2 L therapy among patients with any HIF-2α gene mutation was 14.5 (95% CI: 11.5-24.2) and 9.3 (95% CI: 6.0-18.1) months, respectively, compared with 13.4 (95% CI: 12.9-13.9) and 9.8 (95% CI: 9.3-10.4) months among patients without HIF-2α gene mutations.RESULTSAmong the 9467 adult patients with advanced/metastatic solid tumors included in the analysis, any mutation at the above-mentioned six genes was observed in 1.8% (95% CI: 1.5-2.1) of patients. The mutation prevalence ranged from 0.05% of SDHD to 0.93% of VHL. When further stratified by tumor type, the prevalence of gene mutation in each tumor type was well below 1%, except for VHL with 44% in renal cell carcinomas (RCC). Excluding RCC, the prevalence of any HIF-2α gene mutations in the study population was 0.9% (95% CI: 0.8-1.2). The median overall survival (OS) from 1 and 2 L therapy among patients with any HIF-2α gene mutation was 14.5 (95% CI: 11.5-24.2) and 9.3 (95% CI: 6.0-18.1) months, respectively, compared with 13.4 (95% CI: 12.9-13.9) and 9.8 (95% CI: 9.3-10.4) months among patients without HIF-2α gene mutations.The prevalence of HIF-2α related gene mutations was generally low (<1%) across the 15 solid tumor types, except for VHL in RCC. No significant association between HIF-2α gene mutation status and OS was identified among patients evaluated in this study.DISCUSSION AND CONCLUSIONSThe prevalence of HIF-2α related gene mutations was generally low (<1%) across the 15 solid tumor types, except for VHL in RCC. No significant association between HIF-2α gene mutation status and OS was identified among patients evaluated in this study.
Author	Chen, Cai Dettman, E. J. Cristescu, Razvan Jin, Fan Shao, Changxia Naik, Girish S. Ma, Jiemin Zhong, Wenjun
AuthorAffiliation	1 Merck & Co., Inc. Rahway New Jersey USA
AuthorAffiliation_xml	– name: 1 Merck & Co., Inc. Rahway New Jersey USA
Author_xml	– sequence: 1 givenname: Wenjun orcidid: 0000-0002-0135-4500 surname: Zhong fullname: Zhong, Wenjun organization: Merck & Co., Inc – sequence: 2 givenname: Jiemin surname: Ma fullname: Ma, Jiemin organization: Merck & Co., Inc – sequence: 3 givenname: Cai surname: Chen fullname: Chen, Cai organization: Merck & Co., Inc – sequence: 4 givenname: E. J. surname: Dettman fullname: Dettman, E. J. organization: Merck & Co., Inc – sequence: 5 givenname: Razvan surname: Cristescu fullname: Cristescu, Razvan organization: Merck & Co., Inc – sequence: 6 givenname: Girish S. surname: Naik fullname: Naik, Girish S. organization: Merck & Co., Inc – sequence: 7 givenname: Fan surname: Jin fullname: Jin, Fan organization: Merck & Co., Inc – sequence: 8 givenname: Changxia orcidid: 0000-0003-2091-7599 surname: Shao fullname: Shao, Changxia email: changxie.shao@merck.com organization: Merck & Co., Inc
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38864477$$D View this record in MEDLINE/PubMed
BookMark	eNp1ks9uEzEQxleoiJbSAy-ALHFpD2n9b9fOCVURpZGK4ABny_bOJo527WDvpkTiwCPwKrwID8GT4GRL1SLhg2f0-efPI888Lw588FAULwk-JxjTC6s7fi5YKZ8URxTzciIqxg8e5IfFSUornJfAtBLkWXHIpKw4F-Ko-PYxwka34C0g7Wu0jmHhQ3IJhQYtt-vw1enf3384Xw_WmRZQo20fYpbor5_o9Hp-NaZnaK375a3eogV4QN3Q694Fn5C2MaQc6o3Ob9QohdbVqB-6ENOL4mmj2wQnd_G4-Hz19tPsenLz4d18dnkzsVxgObGCAte41LKsbM0bIc1OYo0lmjRMitqUZkqFxMbmnRlS6cYaRkWDiSElOy7mo28d9Eqto-t03KqgndoLIS6Ujr2zLSjCAShIisEAlyUzjFFrBUDNKKaWZK83o9d6MB3UFnwfdfvI9PGJd0u1CBtFCKlEhXl2OL1ziOHLAKlXnUsW2lZ7CENSDFdSlFxMaUZf_4OuwhB9_qs9VU2xLEWmXj0s6b6Wv13OwNkI7HsRoblHCFa7IVK7IVK7Icrsxcjeuha2_wfV7PI939_4A2DHzP8
Cites_doi	10.1007/s00345-018-2429-x 10.1016/B978-0-444-62702-5.00010-X 10.18632/oncotarget.15201 10.4158/EP15725.OR 10.1210/jc.2018-01968 10.2147/IJNRD.S42097 10.1111/cen.13434 10.1210/jc.2017-00992 10.1016/j.ejca.2017.08.023 10.1097/PAS.0b013e3182260752 10.1210/endrev/bnac025 10.1001/jama.2019.3241 10.3389/fendo.2020.586857 10.1016/j.ejca.2021.04.009 10.1159/000457479 10.15586/jkcvhl.2017.88 10.3390/ijms19092529
ContentType	Journal Article
Copyright	2024 Merck Sharp & Dohme LLC. published by John Wiley & Sons Ltd. 2024 Merck Sharp & Dohme LLC. Cancer Medicine published by John Wiley & Sons Ltd. 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: 2024 Merck Sharp & Dohme LLC. published by John Wiley & Sons Ltd. – notice: 2024 Merck Sharp & Dohme LLC. Cancer Medicine published by John Wiley & Sons Ltd. – notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1002/cam4.7358
DatabaseName	Wiley-Blackwell Open Access Titles CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE Publicly Available Content Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
DocumentTitleAlternate	Zhong et al
EISSN	2045-7634
EndPage	n/a
ExternalDocumentID	oai_doaj_org_article_14ee2e820ebe4853b332cc7eed3202c1 PMC11167604 38864477 10_1002_cam4_7358 CAM47358
Genre	researchArticle Journal Article Observational Study
GeographicLocations	United States--US
GeographicLocations_xml	– name: United States--US
GrantInformation_xml	– fundername: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
GroupedDBID	0R~ 1OC 24P 31~ 53G 5VS 7X7 8-0 8-1 8FE 8FH 8FI 8FJ AAMMB AAZKR ABDBF ABUWG ACCMX ACUHS ACXQS ADBBV ADKYN ADPDF ADRAZ ADZMN AEFGJ AENEX AFKRA AGXDD AIDQK AIDYY ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU D-8 D-9 DIK EBS EJD FYUFA GODZA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE HZ~ IHR ITC KQ8 LK8 M48 M7P M~E O9- OK1 OVD PHGZM PHGZT PIMPY PQGLB PQQKQ PROAC PUEGO RPM TEORI TUS UKHRP WIN AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c4708-c72e4a05a856cd4f78bc72e3fc1a1f387db5b92780bc2783b16afcb327f01b153
IEDL.DBID	DOA
ISICitedReferencesCount	0
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001245074200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2045-7634
IngestDate	Fri Oct 03 12:52:43 EDT 2025 Tue Nov 04 02:05:34 EST 2025 Thu Oct 02 04:02:22 EDT 2025 Sat Nov 29 15:06:50 EST 2025 Mon Jul 21 05:58:45 EDT 2025 Sat Nov 29 03:38:00 EST 2025 Sun Sep 21 06:15:06 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	11
Keywords	epidemiology prevalence HIF‐2α prognosis oncology
Language	English
License	Attribution 2024 Merck Sharp & Dohme LLC. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4708-c72e4a05a856cd4f78bc72e3fc1a1f387db5b92780bc2783b16afcb327f01b153
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ORCID	0000-0003-2091-7599 0000-0002-0135-4500
OpenAccessLink	https://doaj.org/article/14ee2e820ebe4853b332cc7eed3202c1
PMID	38864477
PQID	3068690857
PQPubID	2032540
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_14ee2e820ebe4853b332cc7eed3202c1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11167604 proquest_miscellaneous_3068754792 proquest_journals_3068690857 pubmed_primary_38864477 crossref_primary_10_1002_cam4_7358 wiley_primary_10_1002_cam4_7358_CAM47358
PublicationCentury	2000
PublicationDate	June 2024
PublicationDateYYYYMMDD	2024-06-01
PublicationDate_xml	– month: 06 year: 2024 text: June 2024
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Bognor Regis – name: Hoboken
PublicationTitle	Cancer medicine (Malden, MA)
PublicationTitleAlternate	Cancer Med
PublicationYear	2024
Publisher	John Wiley & Sons, Inc John Wiley and Sons Inc Wiley
Publisher_xml	– name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley
References	2018; 19 2017; 86 2017; 8 2023; 44 2017; 4 2017; 87 2015; 132 2019; 104 2021; 151 2011; 35 2020; 11 2014; 7 2017; 102 2019; 321 2018; 36 2016; 150 2016; 22 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_18_1
References_xml	– volume: 19 issue: 9 year: 2018 article-title: Clinicopathologic significance of VHL gene alteration in clear‐cell renal cell carcinoma: an updated meta‐analysis and review publication-title: Int J Mol Sci – volume: 102 start-page: 3296 issue: 9 year: 2017 end-page: 3305 article-title: Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years publication-title: J Clin Endocrinol Metab – volume: 22 start-page: 302 issue: 3 year: 2016 end-page: 314 article-title: Characteristics and outcomes of metastatic Sdhb and sporadic pheochromocytoma/paraganglioma: an National Institutes of Health study publication-title: Endocr Pract – volume: 132 start-page: 139 year: 2015 end-page: 156 article-title: Von Hippel‐Lindau disease publication-title: Handb Clin Neurol – volume: 4 start-page: 20 issue: 3 year: 2017 end-page: 29 article-title: A review of Von Hippel‐Lindau syndrome publication-title: J Kidney Cancer VHL – volume: 151 start-page: 106 year: 2021 end-page: 114 article-title: Response to systemic therapy in fumarate hydratase‐deficient renal cell carcinoma publication-title: Eur J Cancer – volume: 104 start-page: 2367 issue: 6 year: 2019 end-page: 2374 article-title: Prognosis of malignant pheochromocytoma and paraganglioma (MAPP‐Prono study): a European network for the study of adrenal tumors retrospective study publication-title: J Clin Endocrinol Metab – volume: 11 year: 2020 article-title: The VHL/HIF Axis in the development and treatment of pheochromocytoma/paraganglioma publication-title: Front Endocrinol (Lausanne) – volume: 36 start-page: 1899 issue: 12 year: 2018 end-page: 1911 article-title: Genomics and clinical correlates of renal cell carcinoma publication-title: World J Urol – volume: 150 start-page: 227 issue: 3–4 year: 2016 end-page: 241 article-title: Hypoxia pathway mutations in pheochromocytomas and paragangliomas publication-title: Cytogenet Genome Res – volume: 321 start-page: 1391 issue: 14 year: 2019 end-page: 1399 article-title: Association of patient characteristics and tumor genomics with clinical outcomes among patients with non‐small cell lung cancer using a clinicogenomic database publication-title: JAMA – volume: 44 start-page: 312 issue: 2 year: 2023 end-page: 322 article-title: Hypoxia‐inducible factor 2 Alpha (HIF2alpha) inhibitors: targeting genetically driven tumor hypoxia publication-title: Endocr Rev – volume: 7 start-page: 253 year: 2014 end-page: 260 article-title: Hereditary leiomyomatosis and renal cell carcinoma publication-title: Int J Nephrol Renov Dis – volume: 8 start-page: 25756 issue: 15 year: 2017 end-page: 25782 article-title: Molecular markers of paragangliomas/pheochromocytomas publication-title: Oncotarget – volume: 86 start-page: 1 year: 2017 end-page: 4 article-title: HIF‐2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions publication-title: Eur J Cancer – volume: 35 start-page: 1712 issue: 11 year: 2011 end-page: 1721 article-title: Succinate dehydrogenase‐deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age publication-title: Am J Surg Pathol – volume: 87 start-page: 440 issue: 5 year: 2017 end-page: 450 article-title: Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta‐analysis publication-title: Clin Endocrinol – ident: e_1_2_9_9_1 doi: 10.1007/s00345-018-2429-x – ident: e_1_2_9_13_1 doi: 10.1016/B978-0-444-62702-5.00010-X – ident: e_1_2_9_17_1 doi: 10.18632/oncotarget.15201 – ident: e_1_2_9_16_1 doi: 10.4158/EP15725.OR – ident: e_1_2_9_15_1 doi: 10.1210/jc.2018-01968 – ident: e_1_2_9_6_1 doi: 10.2147/IJNRD.S42097 – ident: e_1_2_9_8_1 doi: 10.1111/cen.13434 – ident: e_1_2_9_14_1 doi: 10.1210/jc.2017-00992 – ident: e_1_2_9_3_1 doi: 10.1016/j.ejca.2017.08.023 – ident: e_1_2_9_10_1 doi: 10.1097/PAS.0b013e3182260752 – ident: e_1_2_9_7_1 doi: 10.1210/endrev/bnac025 – ident: e_1_2_9_11_1 doi: 10.1001/jama.2019.3241 – ident: e_1_2_9_2_1 doi: 10.3389/fendo.2020.586857 – ident: e_1_2_9_18_1 doi: 10.1016/j.ejca.2021.04.009 – ident: e_1_2_9_4_1 doi: 10.1159/000457479 – ident: e_1_2_9_5_1 doi: 10.15586/jkcvhl.2017.88 – ident: e_1_2_9_12_1 doi: 10.3390/ijms19092529
SSID	ssj0000702671
Score	2.3017757
Snippet	Introduction Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC,... Hypoxia-inducible factor-2α (HIF-2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH,... IntroductionHypoxia-inducible factor-2α (HIF-2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC,... Abstract Introduction Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA,...
SourceID	doaj pubmedcentral proquest pubmed crossref wiley
SourceType	Open Website Open Access Repository Aggregation Database Index Database Publisher
StartPage	e7358
SubjectTerms	Adult Aged Basic Helix-Loop-Helix Transcription Factors - genetics Bladder cancer Cancer therapies Colorectal cancer Datasets Electronic health records Endometrial cancer epidemiology Female Gastric cancer Genes HIF‐2α Humans Hypoxia Hypoxia-inducible factors Kidney cancer Liver cancer Lung cancer Male Medical prognosis Melanoma Mesothelioma Metastases Metastasis Middle Aged Mutation Neoplasms - epidemiology Neoplasms - genetics Neoplasms - mortality Neoplasms - pathology oncology Ovaries Patients Point mutation Population Population studies Prevalence Prognosis Prostate Renal cell carcinoma Retrospective Studies Solid tumors Tumors
SummonAdditionalLinks	– databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LbtQwFLWgINQN70egIINYlEXa-JHYWaFSMSoSrboA1F3kJ43EJNPJpNDP4kf4JnydzNARjw27KI4lO_fYvva9Pgehl5m0hTVWpz73LuWEFqkiBWi9eOuJDXNl5Cn49F4cHcmTk_J4PHDrxrTK5ZwYJ2rbGjgj32Vwl6EEPvbXs7MUVKMgujpKaFxF14AlgcXUvePVGUuAMy0EWRIKZXTXqCnfEQwE3i8tQ5Gt_08u5u-Zkpc92LgETW79b-Nvo5uj84n3BrTcQVdccxfdOBzD6_fQORA6qXgNCavGYkjeatqu7nDr8enFrP1WqzRs4ntT6y8OD1o9Kf3xHW8fvJvAwysMEsdf1QUOwHR42g-R_g6r-B_wMuUAB8jXFi_6aTvv7qOPk7cf9g_SUZghNVxkMjWCOq6yXMm8MJZ7ITW8Yt4QRTyTwupcl1TITBtQ8tCkUN5oRoXPiA52eoA2mrZxjxAOVVhuTOmlc7w0wV-BKyumpAEppcvKBL1Y2qmaDfwb1cC0TCswZgXGTNAbsODqA6DMji_a-edqHIFhj-McdcHhCbDlwUnRjFFjRPARQELekARtLW1XjeO4q34ZLkHPV8VhBEJYRTWu7YdvRM5FSRP0cIDLqiVMyuBwilBbrgFpranrJU19Glm-CUTIiownaDti7u_dr_b3DkFBWj7-dxeeoM3QUz4kum2hjcW8d0_RdXO-qLv5szh0fgI6CCY5 priority: 102 providerName: ProQuest – databaseName: Wiley-Blackwell Open Access Titles dbid: 24P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbtUwFLVKQagT_tBAQQYxKIO0sePEjhiViqci0aoDQJ1FtmPTSLykenkBKjFgCWyFjbAIVoKvnQSeAAmJWeTYkj_n2te-9jkIPU5ElVe6UrHNrIkZoXksSQ5aL7aypHJzpecpePOSHx2Jk5PieA09Hd_CBH6I6cANLMPP12DgUnW7P0lDtZyzHZ5m4gK6SEgqQLeBsuPpgMVhmeZ-wwWM67GzIzYyCyV0dyq9sh552v4_-Zq_X5n81ZX1a9Hs6n-14hq6MrigeC9g5jpaM80NdPlwCLLfRJ-A1kn6x0hYNhWGK1xN29Udbi0-PT9rP9by--cvbjPf61q9Mzho9rgk-u0r3j54MQufTzDIHX-Q59iB1OB5H6L-HZa-K_B4_QA7-NcVXvbzdtHdQq9nz1_tH8SDSEOsGU9ErDk1TCaZFFmuK2a5UJCUWk0ksanglcpUQblIlAZVD0VyabVKKbcJUW6-vY3Wm7Yxmwi7ImmmdWGFMazQzneB5yu6oA41hUmKCD0ah6o8C1wcZWBdpiX0Ywn9GKFnMIhTBqDP9gnt4m05WKPb7xhDjXN-HISZc1hUmlKtufMXQE5ekwhtjRAoB5vuyhRe0xSgCBChh9NvZ40QYpGNafuQh2eMFzRCdwJippqkQjjnk7vSYgVLK1Vd_dPUp57xm0C0LE9YhLY9mP7e_HJ_7xDUpMXdf896D224VrNwAW4LrS8XvbmPLun3y7pbPPBW9QPJfipZ priority: 102 providerName: Wiley-Blackwell
Title	Prevalence and prognosis of hypoxia‐inducible factor‐2α (HIF‐2α) pathway gene mutations across advanced solid tumors
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.7358 https://www.ncbi.nlm.nih.gov/pubmed/38864477 https://www.proquest.com/docview/3068690857 https://www.proquest.com/docview/3068754792 https://pubmed.ncbi.nlm.nih.gov/PMC11167604 https://doaj.org/article/14ee2e820ebe4853b332cc7eed3202c1
Volume	13
WOSCitedRecordID	wos001245074200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-7634 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702671 issn: 2045-7634 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-7634 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702671 issn: 2045-7634 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-7634 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702671 issn: 2045-7634 databaseCode: M7P dateStart: 20120801 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-7634 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702671 issn: 2045-7634 databaseCode: 7X7 dateStart: 20120801 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-7634 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702671 issn: 2045-7634 databaseCode: BENPR dateStart: 20120801 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-7634 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702671 issn: 2045-7634 databaseCode: PIMPY dateStart: 20120801 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 2045-7634 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702671 issn: 2045-7634 databaseCode: WIN dateStart: 20120101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2045-7634 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702671 issn: 2045-7634 databaseCode: 24P dateStart: 20120101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELZgFyEuiN8lsFQGcVgOYRPHiZ3j7mqrrUSrCvFTTpHj2NpINFk1LbASBx6BV-FFeAiehBm7rVoB4sLFSfyj2J6xPZbH30fIs0hWWaWrMrSpNSGPWRaqOEOuF1vZuIK50uEUvH0pRiM5meTjDaov9Anz8MC-4w5jbgwzsE7B3zisLWWSMK0FTO3I_K3dxgesno3NlJuDBTIrxSsooYgdajXlL0SC1O4bC5DD6f-Tcfm7j-Sm7eoWn_4tcnNpNdIjX9vb5Ipp7pDrw-W5-F3yBZGYlLs_RFVTUfS6atqu7mhr6fnlRfu5Vj-_foP990LX5QdDPc0ORLEf3-nB2aDvX59TZCj-pC4p6JWh04U_qO-oco2hK48BChpbV3S-mLaz7h550z99fXIWLnkVQs1FJEMtmOEqSpVMM11xK2SJUYnVsYptIkVVpmXOhIxKjUQcZZwpq8uECRvFJUyR98lO0zbmAaFQJEm1zq00hucazA28caJzBoLOTZQH5Omqs4sLD59ReKBkVqBECpRIQI5RDOsMiHjtIkAPiqUeFP_Sg4Dsr4RYLIdhVyR4ASZHEP-APFknwwDCUxHVmHbh84iUi5wFZM_LfF2TREqwFwWUllvasFXV7ZSmPncg3TEecGURD8iBU5y_N784ORoiAbR8-D_64RG5AU_uvdn2yc58tjCPyTX9cV53sx65yvgYQjERLpQ9snt8Ohq_6rnx00PXV0jfHQ-G4_fw9W4w-gVccSWh
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFLWqgoAN70eggEEglUVo7DzsLBAqhdGMOjPqoqDuguMHjcQkw2SmZX4KiR_hm_B1kqEjHrsu2EV2LOUm594c29f3IPQs4CpRUuW-iY32I0ITX5AEtF6MMkTZWOnqFHwYsvGYHx2lBxvoW3cWBtIqu5joArWqJKyR74RwliGFeuyvp198UI2C3dVOQqOBxb5entopW_1q8NZ-3-eU9t4d7vX9VlXAlxELuC8Z1ZEIYsHjRKrIMJ5DU2gkEcSEnKk8zlPKeJBLkKHISSKMzEPKTEByAioRNuRfsDSCcpcqeLBa07HuQxNGugJGAd2RYhK9ZCEIyp_57Tl1gD9R2t8zM88yZvfL6137317WdXS1Jdd4t_GGG2hDlzfRpVGbPnALnUDBKuGOWWFRKgzJaWVVFzWuDD5eTquvhfCLUi1kkX_WuNEi8umP73i7P-jBxQsMEs6nYomt42k8WTSZDDUW7r3jLqUCW5cuFJ4vJtWsvo3en4vVd9BmWZX6HsJ2SBhLmRqudZRKy8fgSI5MqfWEVAeph552uMimTX2RrKkkTTMATwbg8dAbQMzqBigJ7hqq2aesjTB2Dqc11ZbQWbeMLAnLw5BKySwHCmlAJfHQVoeVrI1TdfYLKB56suq2EQa2jUSpq0VzD4sjllIP3W3guXqSkHNLqJkdzdeAu_ao6z1lceyqmBPYAUyCyEPbDuN_Nz_b2x2BQja__28THqPL_cPRMBsOxvsP0BVrddQk9W2hzflsoR-ii_JkXtSzR85tMfp43tD_CX-Vgx4
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFLWqgio2vB8pBQwCqSzCxM7DzgKh0jLqqO1oFoC6C44fNFInGSYzLfNZbPkIvglfJxk64rHrgl3kxFKcnHtzYx-fg9DzgKtESZX7JjbajwhNfEES8HoxyhBlc6XTKfh4yIZDfnycjtbQ924vDNAqu5zoErWqJMyR90LYy5CCHnvPtLSI0V7_zeSLDw5SsNLa2Wk0EDnQi3P7-1a_HuzZd_2C0v6797v7fusw4MuIBdyXjOpIBLHgcSJVZBjPoSk0kghiQs5UHucpZTzIJVhS5CQRRuYhZSYgOQHHCJv-rzAQLXe0wdFyfseGEk0Y6cSMAtqTYhy9YiGYy1_4BDqngD-Vt7-zNC9Wz-7z17_xPz-4m-h6W3TjnSZKbqE1Xd5GG0ctreAOOgMhK-G2X2FRKgyktbKqixpXBp8sJtXXQvhFqeayyE81bjyKfPrjG97eH_Th4CUGa-dzscA2IDUezxuGQ42Fewe4o1pgG-qFwrP5uJrWd9GHSxn1PbReVqV-gLDtEsZSpoZrHaXS1mmwVUem1EZIqoPUQ886jGSTRnckaxSmaQZAygBIHnoL6FleAFLhrqGafs7azGP_7bSm2hZ6NlwjW5zlYUilZLY2CmlAJfHQVoebrM1fdfYLNB56ujxtMw8sJ4lSV_PmGhZHLKUeut9AdXknIee20Ga2N18B8cqtrp4pixOnbk5gZTAJIg9tO7z_ffjZ7s4ROGfzzX8P4QnasIjPDgfDg4fomh101HD9ttD6bDrXj9BVeTYr6uljF8EYfbps5P8ED2iL2w
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+and+prognosis+of+hypoxia%E2%80%90inducible+factor%E2%80%902%CE%B1+%28+HIF+%E2%80%902%CE%B1%29+pathway+gene+mutations+across+advanced+solid+tumors&rft.jtitle=Cancer+medicine+%28Malden%2C+MA%29&rft.au=Zhong%2C+Wenjun&rft.au=Ma%2C+Jiemin&rft.au=Chen%2C+Cai&rft.au=Dettman%2C+E.+J.&rft.date=2024-06-01&rft.issn=2045-7634&rft.eissn=2045-7634&rft.volume=13&rft.issue=11&rft_id=info:doi/10.1002%2Fcam4.7358&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_cam4_7358
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7634&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7634&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7634&client=summon